Daily, Low-dose Aspirin May Be Associated with Reduced Ovarian Cancer Risk
Daily, low-dose use of aspirin by women younger than 70 may be associated with reduced risk of ovarian cancer. These findings were published in September 2020 in the journal Gynecologic Oncology.
Using extended follow up data on 41,633 women enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Cancer Screening Trial, Lauren Hurwitz, Ph.D., postdoctoral fellow and Britton Trabert, Ph.D., Earl Stadtman investigator, both in the Metabolic Epidemiology Branch, and colleagues, examined associations between dose, frequency, and duration of aspirin use and ovarian cancer risk among postmenopausal women. They found overall that neither daily low-dose, nor daily or low-dose aspirin regimens were significantly associated with ovarian cancer risk. However, when limiting their analysis to those younger than 70, they observed an inverse association for both aspirin regimens.
Given the limited data of the few existing studies on low-dose aspirin-use and ovarian cancer risk, future studies are needed to investigate the effects of various aspirin regimens among women in the referenced age group.
Hurwitz LM et al. Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial. Gynecologic Oncology. September 2020. DOI: 10.1016/j.ygyno.2020.08.038 [Epub ahead of print]